Cases & Deals

  • Home
  • Practices
  • Provepharm sells U.S. specialty pharma portfolio

Share

Provepharm sells U.S. specialty pharma portfolio

September 2025

Client(s) Provepharm SAS

Jones Day advised Provepharm SAS in the sale of a U.S. specialty pharma portfolio to The Riverside Company's portfolio company, A.forall. The transaction includes four FDA-approved and marketed sterile injectable drugs and two late-stage pipeline assets.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.